EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies

Alan Rawls, Bridget K Diviak, Cameron I Smith iD, Grant W Severson, Sofia A Acosta, Jeanne Wilson-Rawls iD

Biomolecules · 17.10.2023 · 13 (10) · 1536

DOI: 10.3390/biom13101536 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 17.10.2023. Verfasst von Alan Rawls und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Cardiomyopathies. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 253 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Muscular dystrophies are a heterogeneous group of genetic muscle-wasting disorders that are subdivided based on the region of the body impacted by muscle weakness as well as the functional activity of the underlying genetic mutations. A common feature of the pathophysiology of muscular dystrophies is chronic inflammation associated with the replacement of muscle mass with fibrotic scarring. With the progression of these disorders, many patients suffer cardiomyopathies with fibrosis of the cardiac tissue. Anti-inflammatory glucocorticoids represent the standard of care for Duchenne muscular dystrophy, the most common muscular dystrophy worldwide; however, long-term exposure to glucocorticoids results in highly adverse side effects, limiting their use. Thus, it is important to develop new pharmacotherapeutic approaches to limit inflammation and fibrosis to reduce muscle damage and promote repair. Here, we examine the pathophysiology, genetic background, and emerging therapeutic strategies for muscular dystrophies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneCardiomyopathiesHumansHeartInflammationFibrosis

Stichwörter der Autor:innen

DUX4dysferlindystroglycandystrophinemerinfibrosisinflammationlamin Amuscular dystrophysarcoglycan

Autor:innen und Institutionen

  • School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA.
  • Molecular and Cellular Biology Graduate Program, School of Life Sciences, Tempe, AZ 85287 4501, USA.

ORCID-Profile: Cameron I Smith, Jeanne Wilson-Rawls

Zitieren

APA

Rawls, A., Diviak, B. K., Smith, C. I., Severson, G. W., Acosta, S. A., & Wilson-Rawls, J. (2023). Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies. Biomolecules, 13(10), 1536. https://doi.org/10.3390/biom13101536

Vancouver

Rawls A, Diviak BK, Smith CI, Severson GW, Acosta SA, Wilson-Rawls J. Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies. Biomolecules. 2023;13(10):1536. doi:10.3390/biom13101536

BibTeX
@article{Rawls2023,
  author = {Rawls, Alan and Diviak, Bridget K and Smith, Cameron I and Severson, Grant W and Acosta, Sofia A and Wilson-Rawls, Jeanne},
  title = {Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies},
  journal = {Biomolecules},
  year = {2023},
  volume = {13},
  number = {10},
  pages = {1536},
  doi = {10.3390/biom13101536}
}
Kostenlos starten →